Table 4. Univariate analyses of response to therapy, time to progression, and overall survival according to haemoglobin levels.
| RR | P | TTP | P | OS | P | |
|---|---|---|---|---|---|---|
| 5FU DI ⩾1165 mg sqm week −1 | ||||||
| Hb levels ⩾12 g dl−1 | 50.3% (76/151) | 12.8 | 28.1 | |||
| Hb levels<12 g dl−1 | 32.7% (34/104) | 0.005 | 10.1 | 0.002 | 22.0 | <0.01 |
| 5FU DI<1165 mg sqm week −1 | ||||||
| Hb levels ⩾12 g dl−1 | 34.9% (52/149) | 10.8 | 27.8 | |||
| Hb levels<12 g dl−1 | 32.7% (34/104) | 0.7 | 10.2 | 0.33 | 21.6 | <0.05 |
| Infusional regimen | ||||||
| Hb levels ⩾12 g dl−1 | 45.7% (100/219) | 13.0 | 27.5 | |||
| Hb levels<12 g dl−1 | 25.5% (41/161) | <0.0001 | 10.4 | 0.007 | 20.0 | <0.0001 |
| Bolus+infusional regimen | ||||||
| Hb levels ⩾12 g dl−1 | 32.9% (51/151) | 10.1 | 24.3 | |||
| Hb levels<12 g dl−1 | 35.4% (34/96) | 0.8 | 9.1 | 0.02 | 20.3 | NS |
| Therapy with oxaliplatin | ||||||
| Hb levels ⩾12 g dl−1 | 50.0% (107/214) | 12.8 | 28.4 | |||
| Hb levels<12 g dl−1 | 39.4% (56/142) | 0.05 | 10.5 | 0.002 | 22.1 | <0.01 |
| Therapy without oxaliplatin | ||||||
| Hb levels ⩾12 g dl−1 | 27.5% (44/160) | 10.6 | 24.6 | |||
| Hb levels<12 g dl−1 | 18.1% (19/105) | 0.03 | 8.6 | 0.09 | 18.3 | <0.001 |
| PS 0 | ||||||
| Hb levels ⩾12 g dl−1 | 49.8% (110/221) | 13.5 | 30.1 | |||
| Hb levels<12 g dl−1 | 37.9% (44/116) | 0.03 | 10.8 | 0.003 | 25.3 | <0.05 |
| PS 1 | ||||||
| Hb levels ⩾12 g dl−1 | 27.7% (23/83) | 9.6 | 22.3 | |||
| Hb levels<12 g dl−1 | 27.4% (20/73) | NS | 10.0 | NS | 16.3 | NS |
| PS 2 | ||||||
| Hb levels ⩾12 g dl−1 | 44.4% (4/9) | 8.5 | 10.9 | |||
| Hb levels<12 g dl−1 | 19.0% (4/21) | 0.16 | 7.0 | NS | 10.9 | NS |
| Liver mts | ||||||
| Hb levels ⩾12 g dl−1 | 44.8% (116/259) | 12.0 | 25.9 | |||
| Hb levels<12 g dl−1 | 30.8% (61/198) | 0.002 | 9.9 | <0.001 | 20.1 | <0.001 |
| No liver mts | ||||||
| Hb levels ⩾12 g dl−1 | 30.4% (35/115) | 11.2 | 26.6 | |||
| Hb levels<12 g dl−1 | 23.7% (14/59) | NS | 10.4 | NS | 19.0 | <0.05 |
| Lung mts | ||||||
| Hb levels ⩾12 g dl−1 | 44.1% (49/111) | 14.2 | 35.1 | |||
| Hb levels<12 g dl−1 | 31.5% (17/54) | 0.12 | 11.6 | 0.04 | 25.1 | <0.01 |
| No lung mts | ||||||
| Hb levels ⩾ g dl−1 | 38.8% (102/263) | 11.2 | 23.7 | |||
| Hb levels<12 g dl−1 | 28.6% (58/203) | 0.02 | 9.8 | 0.01 | 18.3 | <0.01 |
| Male | ||||||
| Hb levels ⩾12 g dl−1 | 41.2% (106/257) | 11.8 | 27.5 | |||
| Hb levels<12 g dl−1 | 25.8% (33/128) | 0.03 | 9.4 | <0.001 | 18.8 | <0.0001 |
| Female | ||||||
| Hb levels ⩾12 g dl−1 | 38.5% (45/117) | 11.5 | 24.6 | |||
| Hb levels<12 g dl−1 | 32.6% (42/129) | NS | 10.2 | 0.05 | 21.6 | 0.05 |
mts=metastasis; NS=not significant.